Latest News and Press Releases

Myriad Genetics announces senior leadership transition; Sam Raha as CEO and Mark S. Verratti as COO effective April 30, 2025.

Myriad Genetics today announced financial results for its fourth quarter and full-year ended December 31, 2024.

Myriad Genetics entered into a strategic collaboration with PATHOMIQ to exclusively license its AI technology platform for prostate cancer in the US.

Myriad Genetics has been named on the Forbes list of America’s Best Employers 2025.

Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025.

Myriad Genetics and CancerCARE for Life announced an agreement designed to enhance education and access to hereditary cancer testing.

Myriad Genetics announces it was granted two new patents for its Molecular Residual Disease (MRD) assay.

Myriad Genetics and Lumea have signed an agreement to enhance access to the Prolaris and MyRisk Hereditary Cancer tests through BxLink integration.

Myriad Genetics will unveil groundbreaking eight weeks’ gestation NIPT study results at the annual SMFM conference.

Myriad Genetics launches a new educational website providing information about reproductive and prenatal genetic testing called "Know More Sooner."